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Minireview: The Effects of Species Ortholog and SNP
Variation on Receptors for Free Fatty Acids
Brian D. Hudson, Hannah Murdoch, and Graeme Milligan
Molecular Pharmacology Group, Institute of Molecular, Cell, and Systems Biology, College of Medical,
Veterinary, and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom
Although it is widely assumed that species orthologs of hormone-responsive G protein-coupled
receptors will be activated by the same endogenously produced ligand(s), variation in potency,
particularly in cases in which more than 1 receptor responds to the same hormone, can result in
challenges in defining the contribution of individual receptors in different species. This can create
considerably greater issues when using synthetic chemical ligands and, in some cases, may result
in a complete lack of efficacy of such a ligand when used in animal models of pathophysiology. In
man, the concept that distinct responses of individuals to medicines may reflect differences in the
ability of such drugs to bind to or activate single nucleotide polymorphism variants of receptors is
more established as a concept but, in many cases, clear links between such variants that are
associated with disease phenotypes and substantial differences in receptor ligand pharmacology
have been more difficult to obtain. Herein we consider each of these issues for the group of free
fatty acid receptors, FFA1-FFA4, defined to be activated by free fatty acids of varying chain length,
which, based on their production by 1 tissue or location and action in distinct locations, have been
suggested to possess characteristics of hormones. (Molecular Endocrinology 27: 1177–1187, 2013)
In recent years it has become apparent that a wide rangeof biomolecules previously considered simply as inter-
mediates of metabolic activity also act as key sensors of
metabolic state and do so, at least in part, by activating
members of the family of G protein-coupled receptors
(GPCRs) (1, 2). This is true for molecules derived from
each of dietary carbohydrate, lipid, and fiber, and on this
basis, food had been described as a hormone (3). In many
ways the capacity of simple biomolecules derived from
the catabolism of food to signal nutritional status is both
obvious and provides the most immediate means to initi-
ate feedback loops. Moreover, the production of, for ex-
ample, short-chain fatty acids (SCFAs) via fermentation
of dietary fiber by the intestinal microbiota fulfills a key
criterion for definition as a hormone because, as well as
acting directly in the gut in which they are generated,
these molecules function on cell types ranging from adi-
pocytes to immune cells after transport throughout the
systemic circulation.
The low potency of a number of these biomolecules at
the GPCRs at which they are now considered to be the
true endogenous regulators meant that their initial pair-
ing with previously orphan GPCRs was met with a degree
of skepticism because the potencies of the metabolic li-
gands to induce GPCR activation and therefore produce
the modulation of secondary messenger levels and phys-
iological function were much lower than is the case for
many traditional circulating hormones and neuropep-
tides. For example, in initial efforts to identify ligands that
activate the receptors GPR41 and GPR43 (now redesig-
nated FFA3 and FFA2, respectively) (4), it was the recog-
nition that the common feature of a number of apparently
active ligands that shared little or no chemical similarity
was that they were all present as acetate salts (5). This
subsequently resulted in an appreciation that acetate, and
other SCFAs including propionate and butyrate, acti-
vated these 2 GPCRs directly and were indeed the likely
endogenously generated ligands of these receptors. Al-
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though the potency of these molecules at both FFA2 and
FFA3 is indeed modest, this is only to be expected, given
their small size and resultantly low binding energy (6),
and, of key importance, high concentrations of the SC-
FAs, particularly acetate, are present in both the blood (7)
and particularly in the gut lumen (8). This is consistent
with steady-state levels of these ligands being sufficient to
cause a degree of receptor activation and with changes in
SCFA levels being able to modify cellular responsiveness.
The free fatty acid receptors
The human genome encodes more than 800 GPCRs
and approximately 350 of these have either been shown
or are believed to be activated by endogenously produced
ligands (9). Given the key roles of many of these in con-
trolling major physiological responses, the development
of synthetic chemical ligands that act as either agonists or
antagonists of specific GPCRs has been integral to under-
standing the functions of individual receptors. Further-
more, as an extension of this, ligands at many GPCRs are
major components of our armorium ofmedicines tomask
or mitigate symptoms of disease.
Among the large number of GPCRs that respond to
metabolic intermediates, 4 distinct receptors are currently
accepted and defined by their ability to bind and to be
activated by free fatty acids of varying chain length (4).
Free fatty acid receptor (FFA)-1, FFA2, and FFA3 form a
highly related family group. The genes encoding them are
closely linked at chromosome 19q13.1 in man (4) and
therefore presumably developed from a single common
ancestor via gene duplication. Alignment of the protein
sequences of these receptors, linked to an appreciation
that each is activated by the relevant fatty acids but not
the corresponding amides, suggested that conserved, pos-
itively charged residues within the 7-transmembrane he-
lical domains that provide the common architectural fea-
ture of GPCRs, and located close to the extracellular
surface, would be central to binding of the fatty acid
ligands. Mutagenesis studies have defined the central role
of a pair of arginine residues, 1 in transmembrane domain
V and 1 in transmembrane domain VII, in coordinating
the carboxylate moiety of the fatty acids (10, 11). More-
over, a conserved histidine residue in transmembrane do-
main IV and a second histidine (in FFA2 and FFA3, but an
asparagine in FFA1) in transmembrane domain VI, also
contribute to recognition of the carboxylate (10, 11). By
contrast, FFA4 (previously designated GPR120), despite
binding and being activated by an overlapping group of
medium- and longer-chain fatty acids as FFA1, is not
closely related in sequence to the other fatty acid recep-
tors. However, as with FFA1, an arginine residue, in this
case close to the extracellular face of transmembrane do-
main II, provides the interaction point for the carboxylate
of the fatty acids (12, 13).
The expression pattern of free fatty acid receptors
Even for poorly characterized GPCRs, expression pat-
terns, at least as defined by the presence of appropriate
mRNA transcripts, have provided suggestions of possible
functional roles and hinted at potential disease associa-
tions. Indeed, studies based on transcript expression or
promoter activity have been informative for the FFA fam-
ily members as, for example, the high expression of FFA1
mRNA in pancreatic islets and in various enteroendocrine
cells of the gut has been integral in identifying this recep-
tor as a target for the treatment of type 2 diabetes (14, 15).
Similarly, expression of FFA4 transcript in islets, gut, adi-
pocytes, and macrophages (16–18) has suggested that
this might also be an equally appropriate target for the
control of diabetes and hyperglycemia. Furthermore, the
identification of the expression of the FFA2 transcript in
the lower gut and colon as well as in a range of immune
cells (5) has resulted in this receptor being considered as a
possible target for inflammatory diseases of the bowel. By
contrast, although FFA3 transcript is expressed in a num-
ber of immune cell types, it is present in many of these at
relatively low and similar levels. Perhaps because of this,
the therapeutic potential of targeting FFA3 is much less
clear cut or discussed. Although expression studies based
on the receptor transcript have been important, a need
still remains for the development of immunological re-
agents that will allow for direct identification of FFA re-
ceptor protein expression in native cells and tissues. At the
current time, such antibodies are generally of both limited
availability and questionable specificity.
Synthetic ligands for free fatty acid receptors
Knockout mouse models have been described for each
of FFA1-FFA4 (19–22), and these have both provided
insight into the function of each receptor and suggested
disease areas that might be treated by small molecule
pharmacological medicines. However, the overlap of
function of fatty acids that activate FFA2 and FFA3 (23)
and, similarly, of those that activate FFA1 and FFA4 (24)
means that selective synthetic ligands are required to fully
understand the roles of each receptor in human cells and
tissues and in animal models other than mouse.
At the current time, a surprisingly limited set of such
tool compounds are available to the research community.
Partially because FFA1 has attracted themost attention as
a therapeutic target, there is the greatest number of li-
gands available from commercial sources for this recep-
tor. These include the agonists GW9508 (25) and TUG-
424 (26) as well as the antagonist GW1100 (25). By
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contrast, markedly selective orthosteric ligands described
in the primary literature for FFA2, including the agonist
compound 1 [3-benzyl-4-(cyclopropyl-[4-(2,5-dichloro-
phenyl)thiazol-2-yl]amino)-4-oxobutanoic acid] (27) and
the antagonist CATPB [(S)-3-(2-(3-chlorophenyl)acet-
amido)-4-[4-(trifluoromethyl)phenyl]butanoic acid] (27,
28) are not currently available from commercial sources
but were synthesized for the published studies from de-
tails provided in the patent literature. No selective ligands
for FFA3 have yet been published, whereas the only high-
potency and highly selective ligand for FFA4, TUG-891,
has, so far, been described in a single publication (13) and
very recently has become available through commercial
sources. Despite these current limitations, the developing
interest in the potential therapeutic targeting of these re-
ceptors is likely to result in the wider availability of li-
gands in the future.
Species ortholog and single-nucleotide
polymorphism variation in receptor pharmacology
Although species orthologs of many GPCRs are highly
similar in their ability to bind and respond to the endog-
enously produced ligands because there has been evolu-
tionary pressure to maintain function, there are a number
of examples in which physiological adaptation has re-
sulted in variation in potency. An interesting example of
this can be seen for FFA2. In comparisons of the respon-
siveness of human and bovine FFA2 with fatty acids of
varying chain length, Hudson et al (29) noted the re-
sponse of the bovine ortholog to longer chain-length fatty
acids than the human receptor and the lower potency of
the bovine receptor for acetate. Detailed analysis of these
characteristics identified a single cysteine-glycine amino
acid variation that was central to these differences (29).
Moreover, the alignment of FFA2 from a wide range of
species now available from genome sequencing projects
indicated that this variation is seen in all suborder Rumi-
nantia species including the goat, sheep, yak, and zebu.
This suggests that FFA2 from these species will likely
show the same, distinct pharmacology as recorded for the
cow, although it may be some time before this prediction
is tested directly. Interestingly, this may reflect a physio-
logical adaptation to diet as the rumen of cow and, par-
ticularly, sheep contains very high concentrations of SC-
FAs (30). Moreover, as discussed later, there is marked
variation in potency and/or affinity at each of FFA1 and
FFA2 from different species of various synthetic ligands.
In addition to variations in ligand potency between
species orthologs, the possibility also exists that species
orthologs of a receptor may couple with differing efficien-
cies to their downstream effectors, thus adding another
level of complexity that should be considered. For exam-
ple, we find that although both the human and bovine
orthologs of FFA2 efficiently recruit -arrestin-2 as mea-
sured in a bioluminescence resonance energy transfer-
based assay, we have been unable to detect -arrestin-2
recruitment to either the mouse or rat orthologs of FFA2
in this same assay (unpublished observation, B Hudson,
and G Milligan). Although it is unclear whether this rep-
resents a fundamental difference in the ability of the spe-
cies orthologs to recruit -arrestin-2 or instead simply a
limitation of the assay format, this clearly highlights that
verifying the activity of ligands across multiple assay end
points at species orthologs of these receptors is critical. An
appreciation and an understanding of the basis of ligand
selectivity between species are central to defining the is-
sues that might limit interpretation of the effectiveness or
otherwise of various ligands in animal models of disease
or in cells and tissues isolated from different species. A
number of other GPCRs display marked variation be-
tween species in response to various synthetic ligands, and
recent reviews of this issue on both the receptors for his-
tamine (31) and GPR35 (32) provide useful insight.
Even within species, and of particular relevance to the
development and prescription of effective medicines in
man, variation in the sequence of the same GPCR be-
tween individuals, resulting from nonsynonomous single
nucleotide polymorphisms (SNPs), can result in substan-
tial differences in pharmacology and function of the re-
ceptor. The contribution of this to stratified medicine and
the successful use of therapeutics has been dominated to
date by variation in the function and capacity of enzymes
involved in drug metabolism (33). However, variations in
pharmacology can also contribute, and GPCRs are often
linked to disease via such SNPs in genome-wide associa-
tion studies (34).
Free fatty acid receptor 1
Of themembers of the free fatty acid receptor family, it
is FFA1 that has received by far themost attention to date.
This is due in large part to its high level expression in
pancreatic islet -cells and its ability to enhance glucose
stimulated insulin secretion (GSIS) (14). In addition to
this well-established direct effect on insulin secretion in
-cells, FFA1 agonists have also been found to stimulate
glucagon-like peptide-1 (GLP-1) release from enteroen-
docrine cells (15, 35), and it has been demonstrated that
at least part of the beneficial effect of FFA1 agonists on
glycemic control involves indirect actions mediated by
GLP-1 (36). Not surprisingly, given its effects on GSIS
and GLP-1, there has been significant interest in FFA1 as
a novel target for the treatment of type 2 diabetes, and
indeed, at least 1 FFA1 agonist, TAK-875, has now pro-
gressed through phase II clinical trials with generally fa-
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vorable results (37, 38). However, despite its promise as a
therapeutic target, a number of factors, including SNPs in
human FFA1, conflicting results from knockout studies,
differences in species ortholog pharmacology, and differ-
ential biological outcomes of FFA1 agonists between spe-
cies have presented challenges and complicate the use of
animal models to study this receptor.
FFA1 polymorphisms
An examination of the 1000 genomes project database
(39) identifies 29 missense variants of human FFA1. Of
these, only Arg211His has a minor allele frequency
(MAF) greater than 1%, in which the arginine (Arg) vari-
ant is the minor allele with an MAF of 18.2% (Table 1).
One early study examining the effect of the Arg211His
polymorphism in Japanese men indicated that individuals
homozygous for the less common Arg variant had re-
duced serum insulin and -cell function, suggesting that
this polymorphism may contribute to insulin secretion
capacity (40). However, a second study found that this
polymorphism did not contribute to insulin release as-
sessed through oral glucose tolerance tests (41), and both
studies found no differences in allelic frequency between
healthy and diabetic individuals. Furthermore, at least 2
in vitro studies have now examined the pharmacology of
the Arg211His variant and found nomeasurable effect on
FFA1 function (41, 42).
In addition to the relatively common Arg211His poly-
morphism, several rare human polymorphisms of FFA1
have also been examined. For example, 1 study reported
that the MAF of a Gly180Ser polymorphism continu-
ously increased from nonobese (0.42%) to moderately
obese (1.07%) to severely obese (2.60%) individuals (43).
Oral glucose tolerance testing of individuals with this
polymorphism indicated that insulin secretion was signif-
icantly reduced in individuals with the minor Ser allele,
whereas in vitro experiments suggested that this FFA1
variant resulted in a receptor with greatly reduced func-
tion in a Ca2 mobilization assay (43). However, a sub-
sequent study failed to reproduce this reduced function in
vitro (42). A second rare polymorphism, Asp175Asn, has
also been described to reduce the efficacy of FFA1 in vitro
(41), although as with the other FFA1 polymorphisms,
contradictory results found that the pharmacology of this
variant is not different from the wild type (42). These
studies have not, however, examined any potential vari-
ation in function of the synthetic ligands that are currently
undergoing clinical trials, eg, TAK-875, and it would cer-
tainly be of considerable interest to examine this directly.
In addition to the missense polymorphisms, there are
also 2 SNPs upstream of the FFA1 gene (rs1978013 and
rs1978014) that have been associatedwith-cell function
(44). Although this study did not find a statistical link
between either of these SNPs and type 2 diabetes alone,
the haplotype consisting of the T and G alleles did confer
protection (44). Taken together, although several studies
have examined polymorphisms of FFA1, there is at pres-
ent no clear evidence indicating that any of these signifi-
cantly alter FFA1 function or increase risk of obesity and
type 2 diabetes.
Species ortholog variation in pharmacology at
FFA1
Although the most studied of the free fatty acid GP-
CRs, little work has examined potential differences in the
pharmacology between human and rodent orthologs of
FFA1 in detail and the possible implications of this for
preclinical assessment of FFA1 ligands. In cases in which
agonists have been compared between the human and
rodent, perhaps not surprisingly, given that drug devel-
opment programs are typically designed to optimize li-
gands for the human receptor, most synthetic agonists of
FFA1 have been found to be between 2- and 10-fold more
potent in functional assays at human FFA1 compared
with either the mouse or rat orthologs (45–47). One ex-
ception is a series of thiazolidinedione ligands developed
by Merck, which were found to be 4- to 6-fold more
potent at the mouse than the human receptor (48).
Although binding assays to obtain more direct mea-
sures of ligand affinity have been challenging with the
free fatty acid receptors, at least in part due to the
marked lipophilicity of many of the available ligands,
such studies have been carried out with the clinical
candidate TAK-875, and indeed, the affinity of this
compound was found to be approximately 3.5-fold
Table 1. Open Reading Frame SNPs of Human FFA1-
FFA4 That Have Been Linked With Disease or Show
Minor Allele Frequency Greater Than 1%
Variant
Minor
Allele
MAF,
%
FFA1
Asp175Glu Glu 0.2
Gly180Ser Ser 0.2
Arg211His Arg 18.2
FFA2
Ile46Val Val 1.0
Leu211His His 3.6
FFA3
Gln7His His 5.6
Arg45His His 18.5
FFA4
Arg67Cys Cys 14.9
Arg254His/Arg270Hisa His 0.7
a Polymorphism is at position 254 in short isoform of FFA4 and 270 in
long isoform.
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higher at the human (dissociation constant  0.038
M) than at the rat (0.14 M) FFA1 (49).
At least 2 chemical series of FFA1 antagonists have
also now been described; one by GlaxoSmithKline
(GW1100) (25) and the other by Pfizer (50). Although
both series have been successfully used to block FFA1
responses in rodent insulinoma cell lines (25, 51), we find
that, at least in a Ca2 mobilization assay, although
GW1100 has similar activity at human and rodent or-
thologs, the Pfizer compounds are significantly human
selective (Figure 1), suggesting that there are likely to be
significant species ortholog issues to be considered when
using these FFA1 antagonists in nonhuman systems.
In addition to differences in basic ligand pharmacology
between species, several other factors have complicated
the study of FFA1 function in rodent systems. For exam-
ple, although TAK-875 has been found to suppress glu-
cagon release from isolated pancreatic rat islets, in the
same study, it was found to have no such effect on gluca-
gon secretion from human islets (52). Another factor that
has greatly complicated the understanding of FFA1 func-
tion in rodent systems has been the fact that knockout
mouse models of this receptor have often given confusing
or conflicting results. In particular, although FFA1
knockout lines have generally confirmed that fatty acids
mediate acute enhancement of GSIS through FFA1 (53),
knockout models have been less clear on whether the
chronic inhibitory effect of fatty acids on GSIS also re-
flects activation of FFA1. In one study FFA1 knockout
mice were protected from the negative effects of chronic
exposure to fatty acids (53), whereas other studies have
found this not to be the case (19, 48, 54, 55). These
conflicting results led to speculation that either FFA1 ago-
nists or antagonists might be useful therapeutically. This
controversy highlights the need for selective pharmaco-
logical tool compounds with good activity at rodent re-
ceptor orthologs suitable for in vivo work to complement
and confirm the results of knockout studies.
Free fatty acid receptor 2
Both FFA2 and FFA3 are activated by binding of SC-
FAs, although there are distinct differences in potency of
the SCFAs at these receptors (5, 29). FFA2 is activated by
high micromolar or millimolar SCFA concentrations,
most notably acetate (C2) or propionate (C3), and sub-
stantially less so by caproate (C6) and formate (C1). A
rank order of SCFA potency at FFA2 has been described
as C2  C3  C4  C6  C5  C1 (5, 57).
FFA2 is most highly expressed in immune cells, includ-
ing neutrophils, monocytes, and polymorphonuclear cells
(5), stimulating immune cell recruitment in inflammatory
responses (57, 58). It is also present in adipose tissue and
primary adipocytes, in which it promotes adipogenesis by
increasing lipid accumulation (59) and inhibiting lipolysis
(60). FFA2 expression in the enteroendocrine L cells me-
diates SCFA-induced GLP-1 release (61). FFA2 is also
present in pancreatic islets, specifically the -cells, al-
though its role in -cell function remains unclear (62).
Studies with FFA2 knockout mice have shown that these
animals have improved glucose control, reduced body fat
mass, and increased insulin sensitivity (63). However, in
an acute model of colitis, 2 separate studies have reported
conflicting results with FFA2 knockouts, in that one
showed reduced (20) and the other showed heightened
inflammatory responses (58). Altogether these observa-
tions indicate an importance of FFA2 function in the im-
A B
Figure 1. Species ortholog selectivity of FFA1 antagonists. Concentration-response inhibition curves were generated for either GW1100 (A) (25),
or an antagonist from the Pfizer chemical series (B) (50) against a 300-M concentration of TUG-424 (26) using a Ca2 mobilization assay in Flp-In
T-REx 293 cells designed to express either human (black lines) or mouse (gray lines) FFA1. Compound structures for the antagonists are shown as
inserts. For GW1100, similar pIC50 values are observed for human (6.48  0.17) and mouse (6.05  0.07) orthologs, whereas, in contrast, the
Pfizer compound is approximately 100-fold selective for the human ortholog, with pIC50 values of 6.85  0.12 at human compared with 4.73 
0.09 at mouse. hFFA1, human FFA1; mFFA1, mouse FFA1.
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mune system and metabolism. Selective FFA2 ligands
could therefore be of therapeutic benefit.
Free fatty acid receptor 3
FFA3 is activated preferentially by the SCFAs propi-
onate (C3), butyrate (C4), and valerate (C5), with a rank
order potency of C3  C4  C5  C6  C2  C1 (5).
Although FFA2 and FFA3 share the same endogenous
ligands, ligand activation of these receptors initiates dif-
ferent signaling pathways. FFA3 couples solely to Gi/o
signaling, whereas FFA2 signals via Gi/o and Gq, path-
ways (4). FFA3 expression is widespread, but its function
in many of these tissues is unknown. A recent study has
uncovered a role for FFA3 expressed in the sympathetic
ganglion in controlling energy expenditure in the fed state
and during fasting (64). Sympathetic outflow is dysregu-
lated in metabolic disorders such as obesity, thus making
FFA3 a potential drug target for the treatment of such
conditions.
Early FFA3 studies reported that the receptor is highly
expressed in adipose tissue and in adipocyte cell lines (5).
Furthermore, Xiong et al (65) demonstrated that propi-
onate-induced leptin production from adipocytes is me-
diated by FFA3. These observations have since proved to
be controversial, with many conflicting reports as to
whether FFA3 and/or FFA2 is expressed in adipose tissue
and adipocytes (21, 59, 66). A more recent study has now
determined that leptin production in response to SCFAs is
mediated by FFA2, not FFA3 (66). Data from FFA3/
mouse studies have also generated conflicting observa-
tions in terms of the animals’ glucose tolerance levels and
body fat mass (21). It is evident that FFA3 knockdown or
knockout can be associated with concomitant down-reg-
ulation of FFA2 expression (66), thus making data inter-
pretation difficult. FFA3-selective ligands would there-
fore be useful tools in such investigations to dissect FFA2
vs FFA3 responses in tissues in which these receptors are
coexpressed.
FFA3 has been shown to be expressed in pancreatic
-cells and the insulin-producing -cell lines, MIN6,
NIT-1, and TC-6 (62, 66). A patent detailing a group of
FFA3 agonists and antagonists/inverse agonists cites that
these FFA3 ligands can modulate -cell function, eliciting
either inhibitory (FFA3 agonists) or stimulatory (FFA3
antagonists/inverse agonists) effects on insulin secretion
(67). The therapeutic potential of FFA3-selective ligands
in metabolic disorders may therefore be an encouraging
prospect.
Species ortholog variation in pharmacology at
FFA2 and FFA3
The development of novel selective ligands for FFA2
and FFA3 has been complicated further by recent obser-
vations describing pharmacological variation between
the human and rodent orthologs of these receptors (28).
Rodents are routinely used in GPCR drug development to
assess the function and efficacy of potential therapeutic
drugs, which means that variation in pharmacology be-
tween species is likely to confound interpretation of po-
tential drug efficacy. Mammalian species GPCR or-
thologs are assumed to respond to the same ligands.
However, for modulatory GPCRs such as FFA2 and
FFA3, which respond to a number of ligands, the poten-
cies and rank order of function may differ between spe-
cies, which is certainly true for the bovine FFA2 ortholog,
as described earlier (29).
For the human orthologs, acetate (C2) is reported to be
approximately 20-fold more potent at human FFA2 than
human FFA3, whereas propionate (C3) is equally potent
at the 2 receptors. On this basis, C2 has been described as
FFA2 selective, whereas C3 is considered nonselective. In
a recent pharmacological analysis of themouse orthologs,
we found significant differences in C2/C3 selectivity and
ligand potencies from those of the human orthologs (28).
In [35S]GTPS binding assays, C2 was found to be non-
selective at mouse FFA2 and mouse FFA3, whereas C3
was approximately 12-fold more selective for mouse
FFA3 over mouse FFA2. This altered selectivity to C2 and
C3 was as a direct result of changes in SCFA potency at
the mouse ortholog. The orthologs at which the SCFAs
were most potent, human FFA2 and mouse FFA3, dis-
played high levels of constitutive activity, whereas the
orthologs with lower SCFA potency, mouse FFA2 and
human FFA3, showed limited constitutive activity. Con-
stitutive activity and associated SCFA potency of the spe-
cies orthologs was shown to be regulated by the absence
(human FFA2 and mouse FFA3) or presence (mouse
FFA2 and human FFA3) of an extracellular ionic lock
interaction between a nonconserved acidic residue of the
second extracellular loop and arginine residues within the
orthosteric binding pocket (28). As proof of this, the li-
gand-independent activity of the species orthologs could
be reversed by performing reciprocal mutations of the
nonconserved acidic residue, which tended to yield cor-
responding changes in SCFA potency.
Acetate is often used in studies as a FFA2-selective
agonist to differentiate between human FFA2 and human
FFA3 signaling in cells that coexpress these receptors
(57). It has also been used in rodent studies as an indicator
of FFA2 activity (66). As we have now shown, C2 is
actually nonselective between mouse FFA2 and mouse
FFA3, so it is extremely difficult to assess the functional
contributions of FFA2 vs FFA3 using endogenous ligands.
Studies with knockout mice have proved more useful in
defining FFA2 and FFA3 function, although it is clear that
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C2 cannot be used in these mouse models to imply FFA2-
specific function. Furthermore, as described earlier, there
have been some conflicting observations from knockout
mouse models of FFA2 and FFA3, thus making it difficult
to determine whether a positive or negative modulator of
receptor function would be of therapeutic value. To ad-
dress such issues, selective potent ligands that can effec-
tively discriminate between FFA2 and FFA3 in both hu-
man and rodent experimental systems are required.
FFA2 polymorphisms
There are 40 FFA2 missense variants detailed in the
1000 genomes project database (39). The Leu211His al-
lele is the most common verified variant with a MAF
value of 3.6% (Table 1). At present there are no reports of
this polymorphism being of functional significance or be-
ing associated with any disease/clinical phenotype. How-
ever, such a deleterious change in amino acid composition
could possibly impact receptor function. Given its posi-
tion within the receptor’s third intracellular loop, the
Leu211His variation would appear most likely to alter G
protein coupling. Also of note is a rarer missense variant,
Arg255Gln. The Arg residue at this position is a con-
served polar residue at the upper face of transmembrane
domain VII, which tethers SCFAs to their binding site.
Expression of this minor allelic variant would therefore
be anticipated to be unresponsive to
endogenous ligands and hence be-
have as a knockout.
FFA3 polymorphisms
In addition to FFA1, FFA2, and
FFA3, an additional, structurally re-
lated, GPCR sequence, GPR42, is
encoded in tandem at the same posi-
tion on human chromosome
19q13.1 (68). GPR42 is thought to
have arisen by tandem duplication
of FFA3 (GPR41). FFA3 and
GPR42 share 98% sequence iden-
tity, differing at only 6 amino acid
positions (Figure 2), but GPR42 has
been reported to be inactive and a
potential pseudogene (5). Amino
acid position 174 is responsible for
determining functionality of FFA3
and GPR42 because mutation of
Arg174 (found in FFA3) to Trp174
(found in GPR42) makes the recep-
tor nonresponsive to SCFAs (5). The
reciprocalmutation inGPR42 is suf-
ficient to restore partial functional
responsiveness. Although originally
thought to be an inactive pseudogene, the 6 amino acid
differences between FFA3 and GPR42 are now known to
be polymorphic variants (69).
A genotyping study of the GPR41 FFA3 and GPR42
alleles from a population of more than 100 subjects re-
vealed that the functional Arg174 allele was detected in
61% of those subjects at the GPR42 locus (69). Based on
this study, it is likely that a substantial proportion of the
population encode an active GPR42 variant. Coexpres-
sion of FFA3 with an active variant of GPR42 could
therefore influence an individual’s response to FFA3 li-
gands. Furthermore, the discovery that GPR42 may en-
code a functional gene has important implications for
previous FFA3 expression studies. Techniques for deter-
mining mRNA expression, including Northern blot anal-
ysis, TaqMan, and RT-PCR, would fail to discriminate
between FFA3 and GPR42mRNA transcripts. Thus, pre-
viously reported FFA3 mRNA expression data could rep-
resent composites of GPR41 and GPR42 expression.
The 1000 genomes project database (39) also details
51 missense variants of FFA3. The most common allelic
variant is Arg45His, with a MAF score of 18.5% (Table
1). Amino acid position 45 is one of the nonconsensus
residues between FFA3 and GPR42. The His45 minor
allele of FFA3 was reported in 1 subject in the original
Figure 2. Comparisons of the sequence variation of FFA3 and GPR42. Amino acid sequences
corresponding to human FFA3 and human GPR42 were aligned using the ClustalW algorithm.
The 6 polymorphic variants are highlighted in boxes (solid). Predicted transmembrane regions are
boxed (dashed). Accession numbers are as follows: FFA3, O14843; and GPR42, O15529.
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FFA3/GPR42 genetic study (69). This allele is also found
in a number of expressed sequence tag clones (GenBank
accession number CF147780). It is likely that the His45
allele is a benign variant because interchange with the
GPR42 allele at this site, Arg45Cys, did not alter FFA3
function as determined previously (5).
Two relatively rare described missense variants,
Asp158Asn and Arg185Gln, would be expected to have
significant consequential effects on FFA3 function. We
have previously shown that FFA3 residue Asp158 is in-
volved in forming an ionic lock interaction between argi-
nine residues in the SCFA binding pocket that limit li-
gand-independent activation of the receptor (28). The
mouse ortholog, which displays marked constitutive ac-
tivity, has an Asn residue at this position. Expression of
the Asp158Asn allele in humans would therefore yield a
FFA3 receptor with increased constitutive activity and
potential ligand potency for the endogenous agonist li-
gands. Arg185 of FFA3 is conserved between FFA1-FFA3
and is critical for ligand recognition and anchoring of the
carboxylate moiety of the SCFAs to the binding pocket
(10, 11). Mutation at this site has been shown to ablate
SCFA interactions. On this basis, the Arg185Gln variant
would be anticipated to be nonresponsive to SCFAs.
Free fatty acid receptor 4
Although, as noted earlier, lacking substantial homol-
ogy with the other members of the FFA receptor family,
FFA4 is activated by similar long-chain fatty acid ligands
as FFA1. Although FFA4 expression has been reported in
pancreatic islets and -cell lines (18, 62), unlike FFA1,
there is currently no evidence that FFA4 directly stimu-
lates insulin secretion in these cells. Instead, FFA4 activa-
tion appears to affect islet function and insulin secretion
through 2 independent mechanisms: 1) stimulation of
GLP-1 release from gut enteroendocrine cells (16) and 2)
protecting against cell death in pancreatic islet -cells
(18). In addition to these indirect effects on islet function
and insulin secretion, FFA4 is also expressed in immune
cells, shows antiinflammatory properties, and appears to
protect against insulin resistance (17). Considering each
of these factors, FFA4 has received increasing interest in
recent years as a possible therapeutic target for type 2
diabetes and obesity.
FFA4 polymorphisms and isoforms
At least 31 missense polymorphisms are described for
FFA4 in publically available databases (39). However, of
these, only the Arg67Cys polymorphism shows a MAF
greater than 1% (14.9%) (Table 1). One study examining
this polymorphism found no difference in pharmacology
between it and wild-type FFA4 and only a weak trend
toward an association between the polymorphism and
obesity in humans [odds ratio 1.16] (22). In contrast, the
same study also identified a second, less common,
Arg254His (Arg270His in the long isoform of FFA4; see
later text) polymorphism (MAF  0.7%–3%) that ap-
peared to be strongly associated with obesity (odds ratio
odds ratio 1.62). Examination of the in vitro properties of
this polymorphism indicated that the less common His
allele greatly reduced receptor function (22). Findings
that individuals with a reduced functional form of FFA4
are prone to obesity are further supported by animalwork
demonstrating that mice lacking FFA4 develop more se-
vere obesity and insulin resistance than their wild-type
counterparts after being fed a high-fat diet (22).
In addition to the polymorphisms, 2 splice variant iso-
forms of FFA4 have also been described, varying by the
A B
Figure 3. Comparison of FFA4 agonists at human and mouse orthologs. Concentration-response curves were generated for FFA4 agonists -
linolenic acid (aLA), GW9508 (25), TUG-424 (26), and TUG-891 (13) using a bioluminescence resonance energy transfer-based -arrestin-2
recruitment assay in human embryonic kidney 293 cells transfected with either the human (A) or mouse (B) orthologs of FFA4. Although
compounds displayed somewhat higher potency at the mouse ortholog, the rank order of potency of TUG-891  GW9508  TUG-424  aLA
was maintained between species. hFFA4, human FFA4; mFFA4, mouse FFA4.
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presence or absence of a 16-amino acid insertion in the
third intracellular loop (70). Interestingly, the longer iso-
form is present only in humans, making the study of its
function in rodent or other nonhuman systems challeng-
ing. Functionally, it has been found that although the
short isoform of FFA4 couples in vitro to both G protein-
dependent and -arrestin pathways, the long isoform
couples only to the -arrestin response (12), indicating
that the function of FFA4 may be different in humans
from other species in tissues in which the long isoform is
present. At present, although expression of FFA4-long
has been shown in some tissues, particularly in the colon
(71), the broader importance of this isoform and its full
expression pattern in human tissues remain largely
unknown.
Species ortholog variation at FFA4
At present there are very few described potent and
selective synthetic ligands for FFA4. Of these, the only
one currently described in the academic literature, TUG-
891 [compound 43 (13)], was found to have relatively
similar activities at human and mouse orthologs of FFA4.
In addition to compounds reported in the academic liter-
ature, there are also several patents disclosing potent
FFA4 agonists (56, 72, 73); however, few data are dis-
closed, and no information on the activity of these com-
pounds at nonhuman orthologs of FFA4 is currently
available. In our hands, testing a range of both endoge-
nous fatty acids, FFA4 synthetic, and FFA1 synthetic li-
gands that also show activity at FFA4, we found the phar-
macology of most tested ligands at the human and mouse
orthologs of FFA4 to be quite similar in a -arrestin-2
recruitment assay (Figure 3). Although this perhaps sug-
gests species ortholog variation may be less of an issue for
FFA4 than the other FFA receptors, the fact that many
FFA1 selective ligands are less potent at mouse than hu-
man FFA1, but not at mouse than human FFA4, indicates
that the FFA1 selectivity of these compounds will be re-
duced in mouse systems. Furthermore, the specific assay
end pointmeasuredmay influence the observed selectivity
of these compounds, as for example at the human or-
tholog TUG-891 was found to be substantially more
FFA4 selective when assessed by -arrestin-2 recruitment
than when assessed using Ca2 mobilization assays (13).
This highlights the critical importance of assessing these
factors at the appropriate species orthologs across multi-
ple assay end points before selecting FFA1 or FFA4 li-
gands for use in nonhuman cells and tissues to ensure that
the studies actually target the receptor effectively and
selectively.
Conclusions
Most currently studied SNP variants within the open
reading frame of members of the FFA receptor group of
human GPCRs generally appear to have rather modest
effects on the pharmacology and response of these recep-
tors. The potential exceptions to this are the Arg254His
polymorphism of FFA4 and the functionality or other-
wise of GPR42. However, to date, these issues have not
been explored in detail for clinical candidate or even syn-
thetic proof-of-concept ligands, instead centering largely
on the function of the endogenously produced ligands.
These topics will require significantly more attention as
the FFA receptors become better appreciated and more
fully validated therapeutic targets. Considerably wider
variations in ligand pharmacology have been observed
between species orthologs of both FFA1 and, particularly,
FFA2, and considerable attention therefore needs to be
given to assessing this issue before reaching conclusions
on the contribution and role of these receptors in studies
performed in nonhuman species. This is of particular rel-
evance, given the importance of rodent models of both
metabolic diseases and inflammatory conditions.
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